Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma

Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma

Background Resistance to BRAF and MEK inhibitors (BRAFi/MEKi) in metastatic melanoma frequently results in cross-resistance to immune checkpoint inhibitors (ICI), limiting effective treatment options. However, a subset of BRAFi/MEKi-resistant patients remains responsive to second-line ICI, suggestin...

Full description

Saved in:
Bibliographic Details
Main Authors: Grant A McArthur, Reem Saleh, Lorey Smith, Karen E Sheppard, Riyaben P Patel, Lydia Rui Jia Lim, Darius Schenk, Michael K Lee, Emily Lelliott, Aparna D Rao, Shaghayegh Arabi, Anna S Trigos, Nicole Haynes
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e011551.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e011551.full

Similar Items